Nova Mentis Granted Health Canada Section 56 Exemption to Begin Psilocybin Clinical Trial
Vancouver, British Columbia – February 14, 2023 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce it has received an exemption under Section 56 of the Controlled Drugs and
Read More »
February 14, 2023
Nova Mentis Appoints Derek Ivany as Executive Chairman
Vancouver, British Columbia – January 18, 2023 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce the appointment of Derek Ivany to the position of Executive Chairman. In this new role, Mr. Ivany’s mandate
Read More »
January 18, 2023
Nova Mentis Receives Health Canada Approval for First-of-its-Kind Psilocybin Clinical Trial
The human study will evaluate the Company’s proprietary psilocybin drug (NM-1001) in the treatment of Fragile X Syndrome Vancouver, British Columbia – December 22, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for
Read More »
December 22, 2022
Nova Mentis’ Psilocybin Preclinical Study Published in International Science Journal
Microdose Treatment Modulates Cognition Vancouver, British Columbia – December 8, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce that its psilocybin preclinical study has been published in the Journal of Psychopharmacology, a fully
Read More »
December 8, 2022
Nova Submits Phase II A Psilocybin Clinical Trial Application to Health Canada
Microdose Psilocybin Safety and Efficacy Clinical Study in Fragile X Syndrome Vancouver, British Columbia – November 30, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is proud to announce that the company has submitted to
Read More »
November 30, 2022
Nova Mentis Enters into Research Contract with KGK Science for Phase II A Clinical Trial
Nova Mentis Enters into Research Contract with KGK Science for Phase II A Clinical Trial Vancouver, British Columbia – November 17, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (OTCQB: NMLSF) (FSE: HN3Q) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce that it has entered
Read More »
November 17, 2022